Table 4 Univariate and multivariate analyses of overall survival for patients before and after propensity score matching analysis in UICC T3 HCC patients

Age (y), ≥/< 60

0.613

0.131

Gender (female/male)

0.325

0.776

Etiology (others/HBV)

0.161

0.296

PLT (109/L), ≥/<  100

0.994

0.356

PT (sec), ≥/<  13

0.069

0.047

1.167

1.002–1.359

0.087

0.003

1.425

1.128–1.800

AST (U/L), >/≤ 45

0.019

0.008

1.232

1.055–1.439

0.304

ALB (g/L), ≥/< 35

0.403

0.058

TBL (mmol/L), >/≤ 17

0.408

0.937

(C-P) grade A/B, C

0.400

0.338

ALBI (grade2–3/ grade 1)

0.027

0.002

1.246

1.084–1.431

0.810

AFP (ng/mL), ≥/<  400

0.119

0.291

Tumor size (cm) ≥/<  10

0.016

0.004

1.235

1.071–1.424

0.030

0.003

1.406

1.125–1.757

Tumor numbers (n), > 1/1

0.004

0.004

1.334

1.098–1.620

0.022

0.042

1.435

1.014–2.030

UICC stage IIIb /IIIa

0.000

0.000

1.831

1.545–2.171

0.000

0.000

1.831

1.311–2.559

Year of treatment (10−/−09)

0.056

0.039

0.860

0.746–0.993

0.163

Initial treatment (HR/TACE)

0.000

0.000

0.677

0.569–0.806

0.000

0.000

0.646

0.522–0.798